Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), Celcuity (CELC) and Intuitive Surgical (ISRG)
Leerink Partners Initiates Celcuity(CELC.US) With Buy Rating, Announces Target Price $29
Optimistic Outlook on Celcuity's Gedatolisib: A Buy Rating Backed by Clinical Advancements and Market Potential
Express News | Celcuity Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $29
Celcuity(CELC.US) Director Sells US$5,488 in Common Stock
Celcuity To Participate in Jefferies Global Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Celcuity (CELC) and Icon (ICLR)
Celcuity Is Maintained at Buy by Needham
Express News | Celcuity Inc : Needham Cuts Target Price to $23.00 From $24.00
Celcuity Shares Rise 8.2% After $60 Million Offering Prices
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
Celcuity Plans Phase 3 Trial of Potential Breast Cancer Therapy, Receives Additional Term Loan
Express News | Celcuity Inc: Gross Proceeds to Co From Offering Expected to Be $60.0 Mln
Express News | Celcuity Announces Pricing Of 3,871,000 Share Offering At $15.50/Share
Express News | Celcuity Announces Stock Offering at $15.50 per Share
Express News | Celcuity Announces Pricing of Underwritten Common Stock Offering
Express News | Celcuity Inc: Expects to Enroll First Patient in Q2 of 2025
Express News | Celcuity Inc: Received an Additional Term Loan of Approximately $62 Mln
Express News | Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for Hr+/Her2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
Celcuity Is Maintained at Buy by Stifel